
Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target
Jazz Pharmaceuticals (JAZZ) Analyst Ratings
Bulls say
Jazz Pharmaceuticals is supported by a diversified portfolio of nine approved drugs across neuroscience and oncology, with Xywav, Xyrem, Epidiolex, Zepzelca, Rylaze, and Vyxeos providing substantial recurring cash flow and helping offset competitive pressure in the sleep franchise. The company’s outlook is further strengthened by Ziihera’s early launch in gastroesophageal adenocarcinoma, where sales reached $21M in 3Q26 and management sees broader HER2+ expansion potential, alongside steady Epidiolex growth and controlled expenses. Pipeline optionality also matters, with ABS-1230, JZP269, and other oncology and rare-disease programs creating multiple catalysts that could support revenue growth and EBITDA expansion over time.
Bears say
Jazz Pharmaceuticals is viewed negatively because its core narcolepsy franchise is expected to face mounting erosion from generic entrants, Lumryz expansion, and orexin competition, even as 2027 patient growth supports only a flat franchise at about $2.06B. The outlook is further weakened by pipeline and regulatory risk, reimbursement risk, and the possibility that slower-than-expected uptake of commercial products and failed additional indications could limit growth. Oncology adds upside, but it remains a highly competitive and high-risk area, while broader macro headwinds such as tariffs and MFN could pressure both top- and bottom-line performance.
This aggregate rating is based on analysts' research of Jazz Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Jazz Pharmaceuticals (JAZZ) Analyst Forecast & Price Prediction
Start investing in Jazz Pharmaceuticals (JAZZ)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Jazz Pharmaceuticals (JAZZ) Forecast
Jazz Pharmaceuticals (JAZZ) Analyst Forecast & Price Prediction
Start investing in Jazz Pharmaceuticals (JAZZ)
Order type
Buy in
Order amount
Est. shares
0 shares